100 results on '"His, M."'
Search Results
2. Surpoids, obésité : quel impact sur la récidive du cancer du sein ?
- Author
-
His, M., Clavel-Chapelon, F., and Dossus, L.
- Published
- 2016
- Full Text
- View/download PDF
3. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition.
- Author
-
Breeur, M, Ferrari, P, Dossus, L, Jenab, M, Johansson, M, Rinaldi, S, Travis, RC, His, M, Key, TJ, Schmidt, JA, Overvad, K, Tjønneland, A, Kyrø, C, Rothwell, JA, Laouali, N, Severi, G, Kaaks, R, Katzke, V, Schulze, MB, Eichelmann, F, Palli, D, Grioni, S, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, B, Olsen, KS, Sandanger, TM, Nøst, TH, Quirós, JR, Bonet, C, Barranco, MR, Chirlaque, M-D, Ardanaz, E, Sandsveden, M, Manjer, J, Vidman, L, Rentoft, M, Muller, D, Tsilidis, K, Heath, AK, Keun, H, Adamski, J, Keski-Rahkonen, P, Scalbert, A, Gunter, MJ, Viallon, V, Breeur, M, Ferrari, P, Dossus, L, Jenab, M, Johansson, M, Rinaldi, S, Travis, RC, His, M, Key, TJ, Schmidt, JA, Overvad, K, Tjønneland, A, Kyrø, C, Rothwell, JA, Laouali, N, Severi, G, Kaaks, R, Katzke, V, Schulze, MB, Eichelmann, F, Palli, D, Grioni, S, Panico, S, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, B, Olsen, KS, Sandanger, TM, Nøst, TH, Quirós, JR, Bonet, C, Barranco, MR, Chirlaque, M-D, Ardanaz, E, Sandsveden, M, Manjer, J, Vidman, L, Rentoft, M, Muller, D, Tsilidis, K, Heath, AK, Keun, H, Adamski, J, Keski-Rahkonen, P, Scalbert, A, Gunter, MJ, and Viallon, V
- Abstract
BACKGROUND: Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations. METHODS: We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty. RESULTS: Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk. CONCLUSIONS: These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.
- Published
- 2022
4. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., Weiderpass, E., BoutronRuault, M.C., Cadeau, C., His, M., Cox, D.G., Boeing, H., Fortner, R.T., Kaaks, R., Lagiou, P., Trichopoulou, A., Benetou, V., Tumino, R., Panico, S., Sieri, S., Palli, D., Ricceri, F., BuenodeMesquita, H.B(as), Skeie, G., Amiano, P., Sánchez, M.J., Chirlaque, M.D., Barricarte, A., Quirós, J.R., Buckland, G., van Gils, C.H., Peeters, P.H., Key, T.J., Riboli, E., Gylling, B., ZeleniuchJacquotte, A., Gunter, M.J., Romieu, I., and Chajès, V.
- Published
- 2017
- Full Text
- View/download PDF
5. A new pipeline for the normalization and pooling of metabolomics data
- Author
-
Viallon, V., His, M., Rinaldi, S., Breeur, M., Gicquiau, A., Hemon, B., Overvad, K., Tjønneland, A., Rostgaard-Hansen, A.L., Rothwell, J.A., Lecuyer, L., Severi, G., Kaaks, R., Johnson, T., Schulze, M.B., Palli, D., Agnoli, C., Panico, S., Tumino, R., Ricceri, F., Monique Verschuren, W.M., Engelfriet, P., Onland-Moret, C., Vermeulen, R., Nøst, T.H., Urbarova, I., Zamora-Ros, R., Rodriguez-Barranco, M., Amiano, P., Huerta, J.M., Ardanaz, E., Melander, O., Ottoson, F., Vidman, L., Rentoft, M., Schmidt, J.A., Travis, R.C., Weiderpass, E., Johansson, M., Dossus, L., Jenab, M., Gunter, M.J., Bermejo, J.L., Scherer, D., Salek, R.M., Keski-Rahkonen, P., Ferrari, P., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Inorganic Chemistry and Catalysis, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, and Sub Inorganic Chemistry and Catalysis
- Subjects
Normalization (statistics) ,Pooling ,Computer science ,Pipeline (computing) ,Endocrinology, Diabetes and Metabolism ,computer.software_genre ,Microbiology ,Biochemistry ,Generalized linear mixed model ,Statistical power ,Article ,03 medical and health sciences ,Endocrinology ,0302 clinical medicine ,Cancer epidemiology ,Metabolites ,Metabolomics ,Imputation (statistics) ,Càncer ,Molecular Biology ,030304 developmental biology ,Cancer ,0303 health sciences ,Cancer och onkologi ,Bioinformatics (Computational Biology) ,Normalization ,Technical variability ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Missing data ,QR1-502 ,3. Good health ,Diabetes and Metabolism ,Metabolòmica ,030220 oncology & carcinogenesis ,Cancer and Oncology ,Outlier ,Bioinformatik (beräkningsbiologi) ,Data mining ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,computer - Abstract
Pooling metabolomics data across studies is often desirable to increase the statistical power of the analysis. However, this can raise methodological challenges as several preanalytical and analytical factors could introduce differences in measured concentrations and variability between datasets. Specifically, different studies may use variable sample types (e.g., serum versus plasma) collected, treated, and stored according to different protocols, and assayed in different laboratories using different instruments. To address these issues, a new pipeline was developed to normalize and pool metabolomics data through a set of sequential steps: (i) exclusions of the least informative observations and metabolites and removal of outliers, imputation of missing data, (ii) identification of the main sources of variability through principal component partial R-square (PC-PR2) analysis, (iii) application of linear mixed models to remove unwanted variability, including samples’ originating study and batch, and preserve biological variations while accounting for potential differences in the residual variances across studies. This pipeline was applied to targeted metabolomics data acquired using Biocrates AbsoluteIDQ kits in eight case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Comprehensive examination of metabolomics measurements indicated that the pipeline improved the comparability of data across the studies. Our pipeline can be adapted to normalize other molecular data, including biomarkers as well as proteomics data, and could be used for pooling molecular datasets, for example in international consortia, to limit biases introduced by inter-study variability. This versatility of the pipeline makes our work of potential interest to molecular epidemiologists.
- Published
- 2021
6. A New Pipeline for the Normalization and Pooling of Metabolomics Data
- Author
-
IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Inorganic Chemistry and Catalysis, Viallon, V., His, M., Rinaldi, S., Breeur, M., Gicquiau, A., Hemon, B., Overvad, K., Tjønneland, A., Rostgaard-Hansen, A.L., Rothwell, J.A., Lecuyer, L., Severi, G., Kaaks, R., Johnson, T., Schulze, M.B., Palli, D., Agnoli, C., Panico, S., Tumino, R., Ricceri, F., Monique Verschuren, W.M., Engelfriet, P., Onland-Moret, C., Vermeulen, R., Nøst, T.H., Urbarova, I., Zamora-Ros, R., Rodriguez-Barranco, M., Amiano, P., Huerta, J.M., Ardanaz, E., Melander, O., Ottoson, F., Vidman, L., Rentoft, M., Schmidt, J.A., Travis, R.C., Weiderpass, E., Johansson, M., Dossus, L., Jenab, M., Gunter, M.J., Bermejo, J.L., Scherer, D., Salek, R.M., Keski-Rahkonen, P., Ferrari, P., IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Sub Inorganic Chemistry and Catalysis, Viallon, V., His, M., Rinaldi, S., Breeur, M., Gicquiau, A., Hemon, B., Overvad, K., Tjønneland, A., Rostgaard-Hansen, A.L., Rothwell, J.A., Lecuyer, L., Severi, G., Kaaks, R., Johnson, T., Schulze, M.B., Palli, D., Agnoli, C., Panico, S., Tumino, R., Ricceri, F., Monique Verschuren, W.M., Engelfriet, P., Onland-Moret, C., Vermeulen, R., Nøst, T.H., Urbarova, I., Zamora-Ros, R., Rodriguez-Barranco, M., Amiano, P., Huerta, J.M., Ardanaz, E., Melander, O., Ottoson, F., Vidman, L., Rentoft, M., Schmidt, J.A., Travis, R.C., Weiderpass, E., Johansson, M., Dossus, L., Jenab, M., Gunter, M.J., Bermejo, J.L., Scherer, D., Salek, R.M., Keski-Rahkonen, P., and Ferrari, P.
- Published
- 2021
7. Lifestyle correlates of eight breast cancer-related metabolites: a cross-sectional study within the EPIC cohort
- Author
-
His, M, Viallon, V, Dossus, L, Schmidt, JA, Travis, RC, Gunter, MJ, Overvad, K, Kyro, C, Tjonneland, A, Lecuyer, L, Rothwell, JA, Severi, G, Johnson, T, Katzke, V, Schulze, MB, Masala, G, Sieri, S, Panico, S, Tumino, R, Macciotta, A, Boer, JMA, Monninkhof, EM, Olsen, KS, Nost, TH, Sandanger, TM, Agudo, A, Sanchez, M-J, Amiano, P, Colorado-Yohar, SM, Ardanaz, E, Vidman, L, Winkvist, A, Heath, AK, Weiderpass, E, Huybrechts, I, Rinaldi, S, His, M, Viallon, V, Dossus, L, Schmidt, JA, Travis, RC, Gunter, MJ, Overvad, K, Kyro, C, Tjonneland, A, Lecuyer, L, Rothwell, JA, Severi, G, Johnson, T, Katzke, V, Schulze, MB, Masala, G, Sieri, S, Panico, S, Tumino, R, Macciotta, A, Boer, JMA, Monninkhof, EM, Olsen, KS, Nost, TH, Sandanger, TM, Agudo, A, Sanchez, M-J, Amiano, P, Colorado-Yohar, SM, Ardanaz, E, Vidman, L, Winkvist, A, Heath, AK, Weiderpass, E, Huybrechts, I, and Rinaldi, S
- Abstract
BACKGROUND: Metabolomics is a promising molecular tool for identifying novel etiological pathways leading to cancer. In an earlier prospective study among pre- and postmenopausal women not using exogenous hormones, we observed a higher risk of breast cancer associated with higher blood concentrations of one metabolite (acetylcarnitine) and a lower risk associated with higher blood concentrations of seven others (arginine, asparagine, phosphatidylcholines (PCs) aa C36:3, ae C34:2, ae C36:2, ae C36:3, and ae C38:2). METHODS: To identify determinants of these breast cancer-related metabolites, we conducted a cross-sectional analysis to identify their lifestyle and anthropometric correlates in 2358 women, who were previously included as controls in case-control studies nested within the European Prospective Investigation into Cancer and Nutrition cohort and not using exogenous hormones at blood collection. Associations of each metabolite concentration with 42 variables were assessed using linear regression models in a discovery set of 1572 participants. Significant associations were evaluated in a validation set (n = 786). RESULTS: For the metabolites previously associated with a lower risk of breast cancer, concentrations of PCs ae C34:2, C36:2, C36:3, and C38:2 were negatively associated with adiposity and positively associated with total and saturated fat intakes. PC ae C36:2 was also negatively associated with alcohol consumption and positively associated with two scores reflecting adherence to a healthy lifestyle. Asparagine concentration was negatively associated with adiposity. Arginine and PC aa C36:3 concentrations were not associated to any of the factors examined. For the metabolite previously associated with a higher risk of breast cancer, acetylcarnitine, a positive association with age was observed. CONCLUSIONS: These associations may indicate possible mechanisms underlying associations between lifestyle and anthropometric factors, and risk of breast cance
- Published
- 2021
8. A New Pipeline for the Normalization and Pooling of Metabolomics Data
- Author
-
Viallon, V, His, M, Rinaldi, S, Breeur, M, Gicquiau, A, Hemon, B, Overvad, K, Tjonneland, A, Rostgaard-Hansen, AL, Rothwell, JA, Lecuyer, L, Severi, G, Kaaks, R, Johnson, T, Schulze, MB, Palli, D, Agnoli, C, Panico, S, Tumino, R, Ricceri, F, Verschuren, WMM, Engelfriet, P, Onland-Moret, C, Vermeulen, R, Nost, TH, Urbarova, I, Zamora-Ros, R, Rodriguez-Barranco, M, Amiano, P, Huerta, JM, Ardanaz, E, Melander, O, Ottoson, F, Vidman, L, Rentoft, M, Schmidt, JA, Travis, RC, Weiderpass, E, Johansson, M, Dossus, L, Jenab, M, Gunter, MJ, Bermejo, JL, Scherer, D, Salek, RM, Keski-Rahkonen, P, Ferrari, P, Viallon, V, His, M, Rinaldi, S, Breeur, M, Gicquiau, A, Hemon, B, Overvad, K, Tjonneland, A, Rostgaard-Hansen, AL, Rothwell, JA, Lecuyer, L, Severi, G, Kaaks, R, Johnson, T, Schulze, MB, Palli, D, Agnoli, C, Panico, S, Tumino, R, Ricceri, F, Verschuren, WMM, Engelfriet, P, Onland-Moret, C, Vermeulen, R, Nost, TH, Urbarova, I, Zamora-Ros, R, Rodriguez-Barranco, M, Amiano, P, Huerta, JM, Ardanaz, E, Melander, O, Ottoson, F, Vidman, L, Rentoft, M, Schmidt, JA, Travis, RC, Weiderpass, E, Johansson, M, Dossus, L, Jenab, M, Gunter, MJ, Bermejo, JL, Scherer, D, Salek, RM, Keski-Rahkonen, P, and Ferrari, P
- Abstract
Pooling metabolomics data across studies is often desirable to increase the statistical power of the analysis. However, this can raise methodological challenges as several preanalytical and analytical factors could introduce differences in measured concentrations and variability between datasets. Specifically, different studies may use variable sample types (e.g., serum versus plasma) collected, treated, and stored according to different protocols, and assayed in different laboratories using different instruments. To address these issues, a new pipeline was developed to normalize and pool metabolomics data through a set of sequential steps: (i) exclusions of the least informative observations and metabolites and removal of outliers; imputation of missing data; (ii) identification of the main sources of variability through principal component partial R-square (PC-PR2) analysis; (iii) application of linear mixed models to remove unwanted variability, including samples' originating study and batch, and preserve biological variations while accounting for potential differences in the residual variances across studies. This pipeline was applied to targeted metabolomics data acquired using Biocrates AbsoluteIDQ kits in eight case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Comprehensive examination of metabolomics measurements indicated that the pipeline improved the comparability of data across the studies. Our pipeline can be adapted to normalize other molecular data, including biomarkers as well as proteomics data, and could be used for pooling molecular datasets, for example in international consortia, to limit biases introduced by inter-study variability. This versatility of the pipeline makes our work of potential interest to molecular epidemiologists.
- Published
- 2021
9. Prospective analysis of circulating metabolites and breast cancer in EPIC
- Author
-
His, M. Viallon, V. Dossus, L. Gicquiau, A. Achaintre, D. Scalbert, A. Ferrari, P. Romieu, I. Onland-Moret, N.C. Weiderpass, E. Dahm, C.C. Overvad, K. Olsen, A. Tjønneland, A. Fournier, A. Rothwell, J.A. Severi, G. Kühn, T. Fortner, R.T. Boeing, H. Trichopoulou, A. Karakatsani, A. Martimianaki, G. Masala, G. Sieri, S. Tumino, R. Vineis, P. Panico, S. Van Gils, C.H. Nøst, T.H. Sandanger, T.M. Skeie, G. Quirós, J.R. Agudo, A. Sánchez, M.-J. Amiano, P. Huerta, J.M. Ardanaz, E. Schmidt, J.A. Travis, R.C. Riboli, E. Tsilidis, K.K. Christakoudi, S. Gunter, M.J. Rinaldi, S.
- Abstract
Background: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. Methods: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. Results: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70-0.90), asparagine (OR = 0.83 (0.74-0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76-0.90)), aa C36:3 (OR = 0.84 (0.77-0.93)), ae C34:2 (OR = 0.85 (0.78-0.94)), ae C36:2 (OR = 0.85 (0.78-0.88)), and ae C38:2 (OR = 0.84 (0.76-0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11-1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06-1.24)) and PC ae C36:3 (OR = 0.88 (0.82-0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. Conclusions: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies. © 2019 The Author(s).
- Published
- 2019
10. Prospective analysis of circulating metabolites and breast cancer in EPIC
- Author
-
His, M, Viallon, V, Dossus, L, Gicquiau, A, Achaintre, D, Scalbert, A, Ferrari, P, Romieu, I, Onland-Moret, NC, Weiderpass, E, Dahm, CC, Overvad, K, Olsen, A, Tjonneland, A, Fournier, A, Rothwell, JA, Severi, G, Kuehn, T, Fortner, RT, Boeing, H, Trichopoulou, A, Karakatsani, A, Martimianaki, G, Masala, G, Sieri, S, Tumino, R, Vineis, P, Panico, S, van Gils, CH, Nost, TH, Sandanger, TM, Skeie, G, Quiros, JR, Agudo, A, Sanchez, M-J, Amiano, P, Maria Huerta, J, Ardanaz, E, Schmidt, JA, Travis, RC, Riboli, E, Tsilidis, KK, Christakoudi, S, Gunter, MJ, Rinaldi, S, His, M, Viallon, V, Dossus, L, Gicquiau, A, Achaintre, D, Scalbert, A, Ferrari, P, Romieu, I, Onland-Moret, NC, Weiderpass, E, Dahm, CC, Overvad, K, Olsen, A, Tjonneland, A, Fournier, A, Rothwell, JA, Severi, G, Kuehn, T, Fortner, RT, Boeing, H, Trichopoulou, A, Karakatsani, A, Martimianaki, G, Masala, G, Sieri, S, Tumino, R, Vineis, P, Panico, S, van Gils, CH, Nost, TH, Sandanger, TM, Skeie, G, Quiros, JR, Agudo, A, Sanchez, M-J, Amiano, P, Maria Huerta, J, Ardanaz, E, Schmidt, JA, Travis, RC, Riboli, E, Tsilidis, KK, Christakoudi, S, Gunter, MJ, and Rinaldi, S
- Abstract
BACKGROUND: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk. METHODS: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression. RESULTS: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70-0.90), asparagine (OR = 0.83 (0.74-0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76-0.90)), aa C36:3 (OR = 0.84 (0.77-0.93)), ae C34:2 (OR = 0.85 (0.78-0.94)), ae C36:2 (OR = 0.85 (0.78-0.88)), and ae C38:2 (OR = 0.84 (0.76-0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11-1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06-1.24)) and PC ae C36:3 (OR = 0.88 (0.82-0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity. CONCLUSIONS: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies.
- Published
- 2019
11. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: Results from the EPIC cohort
- Author
-
Sarink, D. Schock, H. Johnson, T. Chang-Claude, J. Overvad, K. Olsen, A. Tjønneland, A. Arveux, P. Fournier, A. Kvaskoff, M. Boeing, H. Karakatsani, A. Trichopoulou, A. La Vecchia, C. Masala, G. Agnoli, C. Panico, S. Tumino, R. Sacerdote, C. Van Gils, C.H. Peeters, P.H.M. Weiderpass, E. Agudo, A. Rodríguez-Barranco, M. Huerta, J.M. Ardanaz, E. Gil, L. Kaw, K.T. Schmidt, J.A. Dossus, L. His, M. Aune, D. Riboli, E. Kaaks, R. Fortner, R.T.
- Subjects
musculoskeletal diseases - Abstract
Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis. Methods: Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models. Results: Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis. Conclusions: High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts. © 2018 The Author(s).
- Published
- 2018
12. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., Weiderpass, E., Boutron-Ruault, M. C., Cadeau, C., His, M., Cox, D. G., Boeing, H., Fortner, R. T., Kaaks, R., Lagiou, P., Trichopoulou, A., Benetou, V., Tumino, R., Panico, S., Sieri, S., Palli, D., Ricceri, F., Bueno-de-Mesquita, H. Bas, Skeie, G., Amiano, P., Sánchez, M. J., Chirlaque, M. D., Barricarte, A., Quirós, J. R., Buckland, G., van Gils, C. H., Peeters, P. H., Key, T. J., Riboli, E., Gylling, B., Zeleniuch-Jacquotte, A., Gunter, M. J., Romieu, I., Chajès, V., Matejcic, M, de Batlle, J, Ricci, C, Biessy, C, Perrier, F, Huybrechts, I, Weiderpass, E, Boutron Ruault, M. C, Cadeau, C, His, M, Cox, D. G, Boeing, H, Fortner, R. T, Kaaks, R, Lagiou, P, Trichopoulou, A, Benetou, V, Tumino, R, Panico, Salvatore, Sieri, S, Palli, D, Ricceri, F, Bueno de Mesquita, H. B. A, Skeie, G, Amiano, P, Sánchez, M. J, Chirlaque, M. D, Barricarte, A, Quirós, J. R, Buckland, G, van Gils, C. H, Peeters, P. H, Key, T. J, Riboli, E, Gylling, B, Zeleniuch Jacquotte, A, Gunter, M. J, Romieu, I, Chajès, V., University Medical Center Utrecht, and Imperial College Trust
- Subjects
hormone receptor status ,Cancer Research ,MTHFR polymorphism ,Risk Factors ,Neoplasms ,Progesterone ,Medicine(all) ,alcohol ,plasma biomarker ,Single Nucleotide ,vitamin B12 ,Middle Aged ,Multicenter Study ,Europe ,Vitamin B 12 ,Oncology ,Female ,breast cancer ,folate ,plasma biomarkers ,Adult ,Aged ,Alcohol Drinking ,Biomarkers ,Breast Neoplasms ,Case-Control Studies ,Diet ,Estrogens ,Folic Acid ,Folic Acid Deficiency ,Follow-Up Studies ,Genes, erbB-2 ,Humans ,Life Style ,Methylenetetrahydrofolate Reductase (NADPH2) ,Neoplasms, Hormone-Dependent ,Polymorphism, Single Nucleotide ,Vitamin B 12 Deficiency ,Journal Article ,Oncology & Carcinogenesis ,Hormone-Dependent ,Polymorphism ,erbB-2 ,hormone receptor statu ,VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 ,VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 ,Genes ,1112 Oncology And Carcinogenesis - Abstract
This is the peer reviewed version of the following article: Matejcic, M., De Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., ... Chajès, V. (2017). Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort. International Journal of Cancer, 140(6), 1246-1259. https://doi.org/10.1002/ijc.30536, which has been published in final form at https://doi.org/10.1002/ijc.30536. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Epidemiological studies have reported inconsistent findings for the association between B vitamins and breast cancer (BC) risk. We investigated the relationship between biomarkers of folate and vitamin B12 and the risk of BC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Plasma concentrations of folate and vitamin B12 were determined in 2,491 BC cases individually matched to 2,521 controls among women who provided baseline blood samples. Multivariable logistic regression models were used to estimate odds ratios by quartiles of either plasma B vitamin. Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed. Plasma levels of folate and vitamin B12 were not significantly associated with the overall risk of BC or by hormone receptor status. A marginally positive association was found between vitamin B12 status and BC risk in women consuming above the median level of alcohol (ORQ4‐Q1 = 1.26; 95% CI 1.00–1.58; Ptrend = 0.05). Vitamin B12 status was also positively associated with BC risk in women with plasma folate levels below the median value (ORQ4‐Q1 = 1.29; 95% CI 1.02–1.62; Ptrend = 0.03). Overall, folate and vitamin B12 status was not clearly associated with BC risk in this prospective cohort study. However, potential interactions between vitamin B12 and alcohol or folate on the risk of BC deserve further investigation.
- Published
- 2016
13. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.
- Author
-
Lafourcade, A, His, M, Baglietto, L, Boutron-Ruault, M-C, Dossus, L, Rondeau, V, Lafourcade, A, His, M, Baglietto, L, Boutron-Ruault, M-C, Dossus, L, and Rondeau, V
- Abstract
BACKGROUND: In addition to tumor characteristics and lifestyle factors, cancer relapses are often related to the risk of death but have not been jointly studied. We investigate the prognostic factors of recurrent events and death after a diagnosis of breast cancer and predict individual deaths including a history of recurrences. METHODS: The E3N (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale) study is a prospective cohort study that was initiated in 1990 to investigate factors associated with the most common types of cancer. Overall survival and three types of recurrent events were considered: locoregional recurrence, metastasis, and second primary breast cancer. Recurrent events and death were analyzed using a joint frailty model. RESULTS: The analysis included 4926 women from the E3N cohort diagnosed with a first primary invasive breast cancer between June 1990 and June 2008; during the follow-up, 1334 cases had a recurrence (median time of follow-up is 7.2 years) and 469 women died. Cases with high grade, large tumor size, axillary nodal involvement, and negative estrogen and progesterone receptors had a higher risk of recurrence or death. Furthermore, smoking increased the risk of relapse. For cases with a medium risk profile in terms of tumor characteristics and lifestyle factors, the probability of dying between 5 and 10 years after diagnosis was 6, 20 and 36% for 0, 1 or 2 recurrences within the first 5 years after diagnosis, respectively. CONCLUSIONS: Our study showed the importance of considering baseline lifestyle characteristics and history of relapses to dynamically predict the risk of death in breast cancer cases. Medical experience coupled with an estimate of a patient's survival probability that considers all available information for this patient would enable physicians to make better informed decisions regarding their actions and thus improve clinical output.
- Published
- 2018
14. A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study
- Author
-
Chajes, V. Assi, N. Biessy, C. Ferrari, P. Rinaldi, S. and Slimani, N. Lenoir, G. M. Baglietto, L. His, M. and Boutron-Ruault, M. C. Trichopoulou, A. Lagiou, P. Katsoulis, M. Kaaks, R. Kuehn, T. Panico, S. Pala, V. Masala, G. Bueno-de-Mesquita, H. B. Peeters, P. H. van Gils, C. and Hjartaker, A. Olsen, K. Standahl Barnung, R. Borgund and Barricarte, A. Redondo-Sanchez, D. Menendez, V. Amiano, P. and Wennberg, M. Key, T. Khaw, K. T. Merritt, M. A. and Riboli, E. Gunter, M. J. Romieu, I.
- Abstract
Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting. We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours. A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4-Q1) 1.37; 95% confidence interval (CI), 1.14-1.64; P for trend = 0.0001, q value = 0.004] as well as a high desaturation index (DI16) (16:1n-7/16:0) [OR (Q4-Q1), 1.28; 95% C, 1.07-1.54; P for trend = 0.002, q value = 0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3-T1)=2.01; 95% CI, 1.03-3.90; P for trend = 0.047], whereas no association was found for ER-positive tumours (P-heterogeneity =0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor. These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.
- Published
- 2017
15. Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort
- Author
-
Sarink, D. Schock, H. Johnson, T. Overvad, K. Holm, M. Tjønneland, A. Boutron-Ruault, M.-C. His, M. Kvaskoff, M. Boeing, H. Lagiou, P. Papatesta, E.-M. Trichopoulou, A. Palli, D. Pala, V. Mattiello, A. Tumino, R. Sacerdote, C. Bueno-De-Mesquita, H.B. Van Gils, C.H. Peeters, P.H. Weiderpass, E. Agudo, A. Sánchez, M.-J. Chirlaque, M.-D. Ardanaz, E. Amiano, P. Khaw, K.T. Travis, R. Dossus, L. Gunter, M. Rinaldi, S. Merritt, M. Riboli, E. Kaaks, R. Fortner, R.T.
- Abstract
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1, 976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n=1, 598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); Ptrend=0.20], but not ER-disease. For both ER+and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR-disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend=0.03]. This study provides the first largescale prospective data on circulating sRANKLand breast cancer. We observed limited evidence for an association between sRANKLand breast cancer risk. Cancer Prev Res; 10(9); 525-34. © 2017 American Association for Cancer Research.
- Published
- 2017
16. Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M. de Batlle, J. Ricci, C. Biessy, C. Perrier, F. Huybrechts, I. Weiderpass, E. Boutron-Ruault, M.C. Cadeau, C. His, M. Cox, D.G. Boeing, H. Fortner, R.T. Kaaks, R. Lagiou, P. Trichopoulou, A. Benetou, V. Tumino, R. Panico, S. Sieri, S. Palli, D. Ricceri, F. Bueno-de-Mesquita, H.B. Skeie, G. Amiano, P. Sánchez, M.J. Chirlaque, M.D. Barricarte, A. Quirós, J.R. Buckland, G. van Gils, C.H. Peeters, P.H. Key, T.J. Riboli, E. Gylling, B. Zeleniuch-Jacquotte, A. Gunter, M.J. Romieu, I. Chajès, V.
- Abstract
Epidemiological studies have reported inconsistent findings for the association between B vitamins and breast cancer (BC) risk. We investigated the relationship between biomarkers of folate and vitamin B12 and the risk of BC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Plasma concentrations of folate and vitamin B12 were determined in 2,491 BC cases individually matched to 2,521 controls among women who provided baseline blood samples. Multivariable logistic regression models were used to estimate odds ratios by quartiles of either plasma B vitamin. Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed. Plasma levels of folate and vitamin B12 were not significantly associated with the overall risk of BC or by hormone receptor status. A marginally positive association was found between vitamin B12 status and BC risk in women consuming above the median level of alcohol (ORQ4-Q1 = 1.26; 95% CI 1.00–1.58; Ptrend = 0.05). Vitamin B12 status was also positively associated with BC risk in women with plasma folate levels below the median value (ORQ4-Q1 = 1.29; 95% CI 1.02–1.62; Ptrend = 0.03). Overall, folate and vitamin B12 status was not clearly associated with BC risk in this prospective cohort study. However, potential interactions between vitamin B12 and alcohol or folate on the risk of BC deserve further investigation. © 2016 UICC
- Published
- 2017
17. Anthropometry and risk of breast cancer among premenopausal women in Latin America: Results from the PRECAMA study
- Author
-
His, M., primary, Biessy, C., additional, Torres-Mejía, G., additional, Sánchez, G.I., additional, Porras, C., additional, and Garmendia, M.L., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort
- Author
-
Epidemiology & Health Economics, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., Weiderpass, E., Boutron-Ruault, M. C., Cadeau, C., His, M., Cox, D. G., Boeing, H., Fortner, R. T., Kaaks, R., Lagiou, P., Trichopoulou, A., Benetou, V., Tumino, R., Panico, S., Sieri, S., Palli, D., Ricceri, F., Bueno-de-Mesquita, H. Bas, Skeie, G., Amiano, P., Sánchez, M. J., Chirlaque, M. D., Barricarte, A., Quirós, J. R., Buckland, G., van Gils, C. H., Peeters, P. H., Key, T. J., Riboli, E., Gylling, B., Zeleniuch-Jacquotte, A., Gunter, M. J., Romieu, I., Chajès, V., Epidemiology & Health Economics, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., Weiderpass, E., Boutron-Ruault, M. C., Cadeau, C., His, M., Cox, D. G., Boeing, H., Fortner, R. T., Kaaks, R., Lagiou, P., Trichopoulou, A., Benetou, V., Tumino, R., Panico, S., Sieri, S., Palli, D., Ricceri, F., Bueno-de-Mesquita, H. Bas, Skeie, G., Amiano, P., Sánchez, M. J., Chirlaque, M. D., Barricarte, A., Quirós, J. R., Buckland, G., van Gils, C. H., Peeters, P. H., Key, T. J., Riboli, E., Gylling, B., Zeleniuch-Jacquotte, A., Gunter, M. J., Romieu, I., and Chajès, V.
- Published
- 2017
19. Biomarkers of folate and vitamin B12, alcohol intake and breast cancer risk: report from the EPIC cohort
- Author
-
Matejcic, M, Ricci, C, Perrier, F, Huybrechts, I, Buckland, G, Amiano, P, Zeleniuch-Jacquotte, A, Gylling, B, Sieri, S, Key, T, van Gils, CH, Peeters, PH, Trichopoulou, A, Lagiou, P, Benetou, V, Sánchez, MJ, His, M, Barricarte, A, Skeie, G, Weiderpass, E, Kaaks, R, Fortner, R, Chirlaque, MD, Cox, DG, Palli, D, Boutron-Ruault, MC, Cadeau, C, Bueno-de-Mesquita, HB, Ricceri, F, Quirós, JR, Tumino, R, Riboli, E, Romieu, I, and Chajès, V
- Abstract
Background. B vitamin status and their interaction with alcohol were suggested to play a role in breast carcinogenesis; however, results from epidemiological studies have been inconsistent. We investigated the association between biomarkers of folate and vitamin B12 and the risk of breast cancer (BC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Methods. Microbiological assays were used to determine plasma concentrations of folate and vitamin B12 in 2,491 BC cases individually matched to 2,521 controls among women participants to the EPIC study who provided baseline blood samples. Multivariable conditional logistic regression models were used to estimate odds ratios by quartiles of plasma B vitamins. Subgroup analyses by menopausal status, hormone receptor status of breast tumors (ER, PR, and HER2), levels of alcohol intake, and MTHFR polymorphisms (677C>T and 1298A>C) were also performed. Results. Plasma concentrations of folate and vitamin B12 were not significantly associated with the overall risk of BC. No significant association emerged by hormone receptor status. A borderline positive association was observed between plasma concentrations of vitamin B12 and BC risk in women consuming above the median level of alcohol (ORQ4-Q1 = 1.30; 95% CI 1.03-1.64; Ptrend = 0.051). Plasma concentrations of vitamin B12 were also marginally associated with BC risk in women with plasma folate levels below the median value (ORQ4-Q1 = 1.26; 95% CI 1.00–1.60; Ptrend = 0.014). However, no significant heterogeneity between subgroups of alcohol intake (Pheterogeneity = 0.14) and plasma folate (Pheterogeneity = 0.059) was found. The association between MTHFR polymorphisms and BC risk in a subsample of this study population was not statistically significant. Conclusions. The present study raises the possibility for a role of vitamin B12 in the etiology of BC, and provides support for potential interactions between nutrients involved in one-carbon metabolism.
- Published
- 2016
20. Cholestérol et risque de cancer du sein : revue systématique et méta-anlyse des études prospectives
- Author
-
Fassier, Philippine, Latino Martel, Paule, His, M., Norat, T., Chan, D. SM, Blacher, J., Hercberg, Serge, Galan, Pilar, Druesne Pecollo, Nathalie, Touvier, Mathilde, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA), Imperial College London, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Santé Publique, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Société Française de Nutrition (SFN). FRA., and Société Francophone Nutrition Clinique et Métabolisme (SFNEP). FRA.
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2014
21. P225: Cholestérol et risque de cancer du sein : revue systématique et méta-analyse des études prospectives
- Author
-
Fassier, P., primary, Latino-Martel, P., additional, His, M., additional, Norat, T., additional, SM Chan, D., additional, Blacher, J., additional, Hercberg, S., additional, Galan, P., additional, Druesne-Pecollo, N., additional, and Touvier, M., additional
- Published
- 2014
- Full Text
- View/download PDF
22. Corpulence et survie après cancer du sein : les résultats de la cohorte prospective E3N, France
- Author
-
His, M., primary, Fagherazzi, G., additional, Mesrine, S., additional, Boutron-Ruault, M.-C., additional, Clavel-Chapelon, F., additional, and Dossus, L., additional
- Published
- 2014
- Full Text
- View/download PDF
23. P016 Étude prospective des liens entre consommation de fibres et risque de cancer du sein
- Author
-
Deschasaux, M., primary, Zelek, L., additional, Pouchieu, C., additional, His, M., additional, Hercberg, S., additional, Galan, P., additional, Latino-Martel, P., additional, and Touvier, M., additional
- Published
- 2013
- Full Text
- View/download PDF
24. P013 Étude prospective des liens entre consommation de fibres et risque de cancer de la prostate : modulation par l’indice de masse corporelle, les concentrations d’insulin-like growth factor et la consommation d’alcool
- Author
-
Deschasaux, M., primary, Pouchieu, C., additional, His, M., additional, Hercberg, S., additional, Latino-Martel, P., additional, and Touvier, M., additional
- Published
- 2013
- Full Text
- View/download PDF
25. O41 Associations prospectives entre biomarqueurs sériques du métabolisme lipidique et risque de cancer (global, sein et prostate)
- Author
-
His, M., primary, Zelek, L., additional, Deschasaux, M., additional, Pouchieu, C., additional, Kesse-Guyot, E., additional, Hercberg, S., additional, Galan, P., additional, Latino-Martel, P., additional, Blacher, J., additional, and Touvier, M., additional
- Published
- 2013
- Full Text
- View/download PDF
26. [Mecagro : a set of approaches to support equipment advice in Picardie]
- Author
-
Mousset, J., Aslahé, C., Billa, Pierre-Alexis, Boiffin, J., Chatelin, M.H., Chopplet, Marc, Francois, M., Gandon, H., Groëll, F., His, M., Hopquin, J.P., Klein, D., Masset, Bertrand, Papy, François, Quiévreux, D., Soler, Louis Georges, ProdInra, Migration, Inconnu, Département d'agronomie, Institut National de la Recherche Agronomique (INRA), Economie Publique (ECO-PUB), Institut National Agronomique Paris-Grignon (INA P-G)-Institut National de la Recherche Agronomique (INRA), and Unité de recherches sur les systèmes agraires et le développement
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,MECAGRO - Abstract
National audience; La maîtrise des coûts de production, et en particulier ceux liés aux charges de mécanisation, est perçue en Picardie comme un enjeu vital pour le maintien de la rentabilité des exploitations. La nécessité de développer le conseil en agro-équipement d'une part, et l'arrivée de nouveaux outils d'aide à la décision d'autre part, ont constitué les deux idées fortes à l'origine d'un programme de recherche-développement conduit en Picardie par la section Agro-Transfert du Biopôle végétal, les Chambres d'Agriculture et des partenaires de l'INRA. Il s'agissait de mettre en place de nouvelles démarches d'aide au choix d'équipement qui répondent aux besoins des agriculteurs, et qui intègrent les contraintes des organismes de développement. Démarré en 1990, ce programme de recherche-développement a abouti à la création d'un dispositif de conseil appelé Mécagro. Après en avoir présenté le dispositif général, les auteurs développent les démarches mises en oeuvre en situation de conseil individuel, puis en situation de conseil en groupe. Enfin, dans une dernière partie, ils décrivent le déroulement du programme de recherche-développement à l'origine de Mécagro.
- Published
- 1997
27. Le conseil agro-équipement en Picardie : mécagro
- Author
-
Mousset, J., Aslahé, C., Billa, Pierre-Alexis, Boiffin, J., Chatelin, M.H., Chopplet, Marc, Francois, M., Gandon, H., Groëll, F., His, M., Hopquin, J.P., Klein, D., Masset, Bertrand, Papy, S., Quiévreux, D., Soler, Louis Georges, Unité d'Agronomie de Laon-Péronne ( LILL LAON AGRO), Institut National de la Recherche Agronomique (INRA), Economie Publique (ECO-PUB), Institut National Agronomique Paris-Grignon (INA P-G)-Institut National de la Recherche Agronomique (INRA), Unité de recherches sur les systèmes agraires et le développement, and ProdInra, Migration
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,MECAGRO ,ComputingMilieux_MISCELLANEOUS - Abstract
National audience
- Published
- 1996
28. P016 Étude prospective des liens entre consommation de fibres et risque de cancer du sein
- Author
-
Deschasaux, M., Zelek, L., Pouchieu, C., His, M., Hercberg, S., Galan, P., Latino-Martel, P., and Touvier, M.
- Published
- 2013
- Full Text
- View/download PDF
29. P013 Étude prospective des liens entre consommation de fibres et risque de cancer de la prostate : modulation par l’indice de masse corporelle, les concentrations d’insulin-like growth factor et la consommation d’alcool
- Author
-
Deschasaux, M., Pouchieu, C., His, M., Hercberg, S., Latino-Martel, P., and Touvier, M.
- Published
- 2013
- Full Text
- View/download PDF
30. O41 Associations prospectives entre biomarqueurs sériques du métabolisme lipidique et risque de cancer (global, sein et prostate)
- Author
-
His, M., Zelek, L., Deschasaux, M., Pouchieu, C., Kesse-Guyot, E., Hercberg, S., Galan, P., Latino-Martel, P., Blacher, J., and Touvier, M.
- Published
- 2013
- Full Text
- View/download PDF
31. Prospective analysis of circulating metabolites and breast cancer in EPIC
- Author
-
José María Huerta, Salvatore Panico, Antonia Trichopoulou, Joseph A. Rothwell, Sabina Sieri, Anja Olsen, Christina C. Dahm, Ruth C. Travis, Audrey Gicquiau, Pilar Amiano, Elisabete Weiderpass, N. Charlotte Onland-Moret, Antonio Agudo, Anna Karakatsani, Isabelle Romieu, Paolo Vineis, Mathilde His, Elio Riboli, Marc J. Gunter, Guri Skeie, Tilman Kühn, Augustin Scalbert, Carla H. van Gils, Georgia Martimianaki, Therese Haugdahl Nøst, Anne Tjønneland, Heiner Boeing, Laure Dossus, Pietro Ferrari, Julie A. Schmidt, Rosario Tumino, Konstantinos K. Tsilidis, David Achaintre, Torkjel M. Sandanger, Agnès Fournier, Sofia Christakoudi, María José Sánchez, Vivian Viallon, Renée T. Fortner, Kim Overvad, Giovanna Masala, Sabina Rinaldi, J. Ramón Quirós, Gianluca Severi, Eva Ardanaz, [His,M, Viallon,V, Dossus,L, Gicquiau,A, Achaintre,D, Scalbert,A, Ferrari,P, Weiderpass,E, Gunter,MJ, Rinaldi,S] International Agency for Research on Cancer, Lyon, France. [Romieu,I] Centre for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico. [Onland-Moret,NC, van Gils,CH] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [Dahm,CC, Overvad,K] Department of Public Health, Aarhus University, Aarhus, Denmark. [Overvad,K] Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. [Olsen,A, Tjønneland,A] Danish Cancer Society Research Center, Copenhagen, Denmark. [Tjønneland,A] University of Copenhagen, Copenhagen, Denmark. [Fournier,A, Rothwell,JA, Severi,G] CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Fournier,A, Severi,G] Gustave Roussy, Villejuif, France. [Kühn,T, Fortner,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. [Trichopoulou,A, Karakatsani,A, Martimianaki,G] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, 'ATTIKON' University Hospital, Haidari, Greece. [Masala,G] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network – ISPRO, Florence, Italy. [Sieri,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. [Tumino,R] Cancer Registry and Histopathology Department, 'M.P.Arezzo'Hospital, ASP Ragusa, Ragusa, Italy. [Vineis,P] Italian Institute for Genomic Medicine (IIGM), Turin, Italy. [Vineis,P] MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. [Panico,S] Dipartimento di medicina clinica e chirurgia, Federico II University, Naples, Italy. [Nøst,TH, Sandanger,TM, Skeie,G] Department of Community Medicine, UiT the Arctic University of Norway, Tromso, Norway. [Skeie,G] Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Universidad de Granada, Granada, Spain. [Sánchez,MJ, Amiano,P, Huerta,JM, Ardanaz,E] CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain. [Amiano,P] Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Schmidt,JA, Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Riboli,E, Tsilidis,KK, Christakoudi,S] Department of Epidemiology and Biostatistics, Imperial College London, St Mary’s Campus, Norfolk Place, London, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. [Christakoudi,S] MRC Centre for Transplantation, King’s College London, Great Maze Pond, London, SE1 9RT, UK, This work was funded by the French National Cancer Institute (grant number 2015-166). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), European Research Council (ERC-2009-AdG 232997), and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236), Navarra, and the CERCA Program (Generalitat de Catalunya) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).
- Subjects
0301 basic medicine ,Oncology ,lcsh:Medicine ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings] ,Mass Spectrometry ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Cohort Studies ,0302 clinical medicine ,Breast cancer ,Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings] ,Risk Factors ,Estudios prospectivos ,Prospective Studies ,Prospective cohort study ,11 Medical and Health Sciences ,Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings] ,education.field_of_study ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings] ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Incidence ,Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Metabolomics [Medical Subject Headings] ,General Medicine ,Metabolómica ,Middle Aged ,metabolomics ,3. Good health ,Research Design ,030220 oncology & carcinogenesis ,Cohort ,Neoplasias de la mama ,Female ,Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings] ,Cohort study ,Research Article ,prospective study ,Adult ,medicine.medical_specialty ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings] ,Population ,Breast Neoplasms ,Càncer de mama ,03 medical and health sciences ,breast cancer ,Internal medicine ,Cell Line, Tumor ,General & Internal Medicine ,medicine ,Journal Article ,Metabolomics ,Humans ,Prospective study ,education ,Persons::Persons::Age Groups::Adult [Medical Subject Headings] ,Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings] ,Aged ,business.industry ,lcsh:R ,Case-control study ,Cancer ,Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Odds ratio ,medicine.disease ,030104 developmental biology ,Check Tags::Female [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings] ,Case-Control Studies ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::Mass Spectrometry [Medical Subject Headings] ,Biomarkers - Abstract
BackgroundMetabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk.MethodsA nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression.ResultsAmong women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity.ConclusionsThese findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies.
- Published
- 2019
32. Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort
- Author
-
Miren Dorronsoro, Marc J. Gunter, Mathilde His, Helena Schock, Sabina Sieri, Maria Dolores Chirlaque, Aurélie Affret, Rudolf Kaaks, Elisabete Weiderpass, H. Bas Bueno-de-Mesquita, Philippos Orfanos, Melissa A. Merritt, Anne Tjønneland, Domenico Palli, J. Ramón Quirós, María José Sánchez, Theron Johnson, Danja Sarink, Eva Ardanaz, Antonio Agudo, Renée T. Fortner, Laure Dossus, Timothy J. Key, Kim Overvad, Rosario Tumino, Androniki Naska, Petra H.M. Peeters, Heiner Boeing, Amalia Mattiello, Anja Olsen, Sabina Rinaldi, Eiliv Lund, Antonia Trichopoulou, Carla H. van Gils, Marie-Christine Boutron-Ruault, Kay-Tee Khaw, Elio Riboli, Fulvio Ricceri, Khaw, Kay-Tee [0000-0002-8802-2903], Apollo - University of Cambridge Repository, University Medical Center Utrecht, Imperial College Trust, [Fortner,RT, Sarink,D, Schock,H, Johnson,T, Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Tjønneland,A, Olsen,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Overvad,K] Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. [Affret,A, His,M, Boutron-Ruault,MC] Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France. [Affret,A, Boutron-Ruault,MC] Villejuif, France. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Naska,A, Orfanos,P] Hellenic Health Foundation, Athens, Greece. [Trichopoulou,A, Orfanos,P] WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy. [Sieri,S] Epidemiology and Prevention Unit, Department of Preventive & Predictive Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Mattiello,A] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic - M.p.Arezzo' Hospital, ASP Ragusa, Italy. [Ricceri,F] Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco (TO), Italy. [Ricceri,F] Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Bueno-de-Mesquita,HB, Merritt,MA, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Bueno-de-Mesquita,HB] Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [Peeters,PH, Van Gils,CH] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. [Peeters,PH] MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK. [Weiderpass,E, Lund,E] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Weiderpass,E] Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway. [Weiderpass,E] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [Weiderpass,E] Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer. Cancer Epidemiology Research Program. Catalan Institute of Oncology-IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs. GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Sánchez,MJ, Chirlaque,MD, Ardanaz,E] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Chirlaque,MD] Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque,MD] Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia Research Institute CIBERESP, Basque Regional Health Department, San Sebastian, Spain. [Key,T] Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Khaw,KT] Cancer Epidemiology Unit, University of Cambridge, Cambridge, UK. [Rinaldi,S, Dossus,L, Gunter,M] International Agency for Research on Cancer, Lyon, France., This project was funded by research grant 111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and the National Research Council (Italy), the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, and Navarra, and ISCIII RETIC (RD06/0020) (Spain), the Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
- Subjects
0301 basic medicine ,Oncology ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone [Medical Subject Headings] ,Estrogen receptor ,Progesterone receptor ,Cohort Studies ,0302 clinical medicine ,Breast cancer ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Receptor Activator of Nuclear Factor-kappa B [Medical Subject Headings] ,Risk Factors ,Prospective Studies ,Prospective cohort study ,Medicine(all) ,Osteoprotegerina ,biology ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,11 Medical And Health Sciences ,General Medicine ,Middle Aged ,Necrosi ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,RANK axis ,RANKL ,030220 oncology & carcinogenesis ,Neoplasias de la mama ,Female ,Research Article ,musculoskeletal diseases ,medicine.medical_specialty ,Receptores estrogénicos ,Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings] ,Breast Neoplasms ,Receptores de progesterona ,Receptores de hormonas ,Hormone receptor ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [Medical Subject Headings] ,Càncer de mama ,Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings] ,Necrosis ,03 medical and health sciences ,Osteoprotegerin ,General & Internal Medicine ,Internal medicine ,Journal Article ,medicine ,Humans ,Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings] ,business.industry ,Case-control study ,medicine.disease ,Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Prospective Studies [Medical Subject Headings] ,030104 developmental biology ,Endocrinology ,Case-Control Studies ,Nested case-control study ,Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause::Postmenopause [Medical Subject Headings] ,biology.protein ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Tumor Necrosis Factor Decoy Receptors::Osteoprotegerin [Medical Subject Headings] ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business - Abstract
All Author: Renée T. Fortner, Danja Sarink, Helena Schock, Theron Johnson, Anne Tjønneland, Anja Olsen, Kim Overvad, Aurélie Affret, Mathilde His, Marie-Christine Boutron-Ruault, Heiner Boeing, Antonia Trichopoulou, Androniki Naska, Philippos Orfanos, Domenico Palli, Sabina Sieri, Amalia Mattiello, Rosario Tumino, Fulvio Ricceri, H. Bas Bueno-de-Mesquita, Petra H. M. Peeters, Carla H. Van Gils, Elisabete Weiderpass, Eiliv Lund, J. Ramón Quirós, Antonio Agudo, Maria-José Sánchez, María-Dolores Chirlaque, Eva Ardanaz, Miren Dorronsoro, Tim Key, Kay-Tee Khaw, Sabina Rinaldi, Laure Dossus, Marc Gunter, Melissa A. Merritt, Elio Riboli and Rudolf Kaaks, Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER–, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER– breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER– breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24–3.02]; ptrend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER– disease did not differ by menopausal status at blood collection (phet = 0.97), and we observed no heterogeneity by HT use at blood collection (phet ≥ 0.43) or age at breast cancer diagnosis (phet ≥ 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER– breast cancer., This project was funded by research grant 111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and the National Research Council (Italy); the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, and Navarra, and ISCIII RETIC (RD06/0020) (Spain); the Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
- Published
- 2017
33. A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study
- Author
-
Maria Wennberg, Antonia Trichopoulou, Isabelle Romieu, Laura Baglietto, Aurelio Barricarte, Marc J. Gunter, M. C. Boutron-Ruault, Nada Assi, Petra H.M. Peeters, Michail Katsoulis, Rudolf Kaaks, Veronique Chajes, Anette Hjartåker, Timothy J. Key, Pilar Amiano, R. Borgund Barnung, Kay-Tee Khaw, Mathilde His, C. H. van Gils, Melissa A. Merritt, Pagona Lagiou, Daniel Redondo-Sánchez, Virginia Menéndez, Carine Biessy, Gilbert M. Lenoir, Giovanna Masala, Elio Riboli, V. Pala, Tilman Kühn, K. Standahl Olsen, Nadia Slimani, S. Rinaldi, Pamela Ferrari, Hendrik B. Bueno-de-Mesquita, Salvatore Panico, Chajès, V, Assi, N, Biessy, C, Ferrari, P, Rinaldi, S, Slimani, N, Lenoir, G. M, Baglietto, L, His, M, Boutron ruault, M. C, Trichopoulou, A, Lagiou, P, Katsoulis, M, Kaaks, R, Kühn, T, Panico, Salvatore, Pala, V, Masala, G, Bueno de mesquita, H. B, Peeters, P. H, Van Gils, C, Hjartåker, A, Olsen, Standahl K, Barnung, Borgund R, Barricarte, A, Sanchez, D. Redondo, Menéndez, V, Amiano, P, Wennberg, M, Key, T, Khaw, K. T, Merritt, M. A, Riboli, E, Gunter, M. J, Romieu, I., and Imperial College Trust
- Subjects
0301 basic medicine ,diagnosis ,neoplasms ,epic study ,Prospective evaluation ,breast cancer risk ,Institut Gustave Roussy ,0302 clinical medicine ,Risk Factors ,Receptors ,Prospective Studies ,Progesterone ,Phospholipids ,Tumor ,Fatty Acids ,Hematology ,Middle Aged ,Prognosis ,estrogen receptor negative ,Europe ,Oncology ,Receptors, Estrogen ,030220 oncology & carcinogenesis ,language ,biomarker ,Epic study ,epidemiology ,Female ,Receptors, Progesterone ,biological markers ,medicine.medical_specialty ,Library science ,Breast Neoplasms ,fatty acids ,Danish ,03 medical and health sciences ,Breast cancer ,breast cancer ,Journal Article ,medicine ,Biomarkers, Tumor ,Humans ,Oncology & Carcinogenesis ,phospholipids ,plasma ,breast ,lipogenesis ,VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 ,business.industry ,Public health ,Biomarkers ,EPIC ,Epidemiology ,Fatty acids ,Case-Control Studies ,Follow-Up Studies ,Diet ,Cancer ,biomarkers ,medicine.disease ,Estrogen ,language.human_language ,Cancer registry ,VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 ,desaturation of blood ,030104 developmental biology ,epic trial ,heterogeneity ,diet ,business ,1112 Oncology And Carcinogenesis - Abstract
This is a pre-copyedited, author-produced version of an article accepted for publication in Annals of Oncology following peer review. The version of record Chajès, V., Assi, N., Biessy, C., Ferrari, P., Rinaldi, S., Slimani, N., ... Romieu, I. (2017). A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. Annals of Oncology, 28(11), 2836-2842. https://doi.org/10.1093/annonc/mdx482, is available online at: https://doi.org/10.1093/annonc/mdx482. Background: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting. Materials and methods: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours. Results: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4–Q1) 1.37; 95% confidence interval (CI), 1.14–1.64; P for trend = 0.0001, q value = 0.004] as well as a high desaturation index (DI16) (16:1n–7/16:0) [OR (Q4–Q1), 1.28; 95% C, 1.07–1.54; P for trend = 0.002, q value = 0.037], as biomarkers of de novo lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial trans-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3–T1)=2.01; 95% CI, 1.03–3.90; P for trend = 0.047], whereas no association was found for ER-positive tumours (P-heterogeneity =0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor. Conclusion: These findings suggest that increased de novo lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary trans-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk.
- Published
- 2017
34. Multi-Trait Body Shape Phenotypes and Breast Cancer Risk in Postmenopausal Women: A Causal Mediation Analysis in the UK Biobank Cohort.
- Author
-
Amadou A, Freisling H, Sedlmeier AM, Bohmann P, Fontvieille E, Weber A, Konzok J, Stein MJ, Peruchet-Noray L, Jansana A, Noh H, His M, Gan Q, Baurecht H, and Fervers B
- Subjects
- Humans, Female, United Kingdom epidemiology, Middle Aged, Aged, Mediation Analysis, Risk Factors, Cohort Studies, Body Mass Index, Waist-Hip Ratio, Somatotypes, Insulin-Like Growth Factor I metabolism, Insulin-Like Growth Factor I analysis, UK Biobank, Breast Neoplasms epidemiology, Postmenopause, Phenotype, Biological Specimen Banks
- Abstract
Body shape phenotypes combining multiple anthropometric traits have been linked to postmenopausal breast cancer (BC). However, underlying biological pathways remain poorly understood. This study investigated to what extent the associations of body shapes with postmenopausal BC risk is mediated by biochemical markers. The study included 176,686 postmenopausal women from UK Biobank. Four body shape phenotypes were derived from principal component (PC) analysis of height, weight, body mass index, waist and hip circumferences, and waist-to-hip ratio (WHR). The four-way decomposition of the total effect was used to estimate mediation and interaction effects simultaneously as well as the mediated proportions. After 10.9 years median follow-up, 6,396 incident postmenopausal BC were diagnosed. There was strong evidence of positive associations between PC1 (general obesity) and PC2 (tall, low WHR), and BC risk. The association of PC1 with BC risk was positively mediated by testosterone and negatively by insulin-like growth factor-1 (IGF-1), with the overall proportion mediated (sum of the mediated interaction and pure indirect effect (PIE)) accounting for 11.4% (95% confidence intervals: 5.1 to 17.8%) and -12.2% (-20.5% to -4.0%) of the total effect, respectively. Small proportions of the association between PC2 and BC were mediated by IGF-1 (PIE: 2.8% (0.6 to 4.9%)), and sex hormone-binding globulin (SHBG) (PIE: -6.1% (-10.9% to -1.3%)). Our findings are consistent with differential pathways linking different body shapes with BC risk, with a suggestive mediation through testosterone and IGF-1 in the relationship of a generally obese body shape and BC risk, while IGF-1 and SHBG may mediate a tall/lean body shape-BC risk association., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Application of Metabolomics to Epidemiologic Studies of Breast Cancer: New Perspectives for Etiology and Prevention.
- Author
-
His M, Gunter MJ, Keski-Rahkonen P, and Rinaldi S
- Subjects
- Humans, Female, Prospective Studies, Metabolomics methods, Epidemiologic Studies, Breast Neoplasms epidemiology, Breast Neoplasms etiology, Breast Neoplasms prevention & control
- Abstract
Purpose: To provide an overview on how the application of metabolomics (high-throughput characterization of metabolites from cells, organs, tissues, or biofluids) to population-based studies may inform our understanding of breast cancer etiology., Methods: We evaluated studies that applied metabolomic analyses to prediagnostic blood samples from prospective epidemiologic studies to identify circulating metabolites associated with breast cancer risk, overall and by breast cancer subtype and menopausal status. We provide some important considerations for the application and interpretation of metabolomics approaches in this context., Results: Overall, specific lipids and amino acids were indicated as the most common metabolite classes associated with breast cancer development. However, comparison of results across studies is challenging because of heterogeneity in laboratory techniques, analytical methods, sample size, and applied statistical methods., Conclusion: Metabolomics is being increasingly applied to population-based studies for the identification of new etiologic hypotheses and/or mechanisms related to breast cancer development. Despite its success in applications to epidemiology, studies of larger sample size with detailed information on menopausal status, breast cancer subtypes, and repeated biologic samples collected over time are needed to improve comparison of results between studies and enhance validation of results, allowing potential clinical translation of findings.
- Published
- 2024
- Full Text
- View/download PDF
36. Key takeaways for knowledge expansion of early-career scientists conducting Transdisciplinary Research in Energetics and Cancer (TREC): a report from the TREC Training Workshop 2022.
- Author
-
Kung CP, Skiba MB, Crosby EJ, Gorzelitz J, Kennedy MA, Kerr BA, Li YR, Nash S, Potiaumpai M, Kleckner AS, James DL, Coleman MF, Fairman CM, Galván GC, Garcia DO, Gordon MJ, His M, Hornbuckle LM, Kim SY, Kim TH, Kumar A, Mahé M, McDonnell KK, Moore J, Oh S, Sun X, and Irwin ML
- Subjects
- Humans, Interdisciplinary Research, Program Evaluation methods, Research Personnel education, Neoplasms diagnosis, Neoplasms therapy, Neoplasms epidemiology, Medicine
- Abstract
The overall goal of the annual Transdisciplinary Research in Energetics and Cancer (TREC) Training Workshop is to provide transdisciplinary training for scientists in energetics and cancer and clinical care. The 2022 Workshop included 27 early-to-mid career investigators (trainees) pursuing diverse TREC research areas in basic, clinical, and population sciences. The 2022 trainees participated in a gallery walk, an interactive qualitative program evaluation method, to summarize key takeaways related to program objectives. Writing groups were formed and collaborated on this summary of the 5 key takeaways from the TREC Workshop. The 2022 TREC Workshop provided a targeted and unique networking opportunity that facilitated meaningful collaborative work addressing research and clinical needs in energetics and cancer. This report summarizes the 2022 TREC Workshop's key takeaways and future directions for innovative transdisciplinary energetics and cancer research., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
37. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition.
- Author
-
Breeur M, Ferrari P, Dossus L, Jenab M, Johansson M, Rinaldi S, Travis RC, His M, Key TJ, Schmidt JA, Overvad K, Tjønneland A, Kyrø C, Rothwell JA, Laouali N, Severi G, Kaaks R, Katzke V, Schulze MB, Eichelmann F, Palli D, Grioni S, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita B, Olsen KS, Sandanger TM, Nøst TH, Quirós JR, Bonet C, Barranco MR, Chirlaque MD, Ardanaz E, Sandsveden M, Manjer J, Vidman L, Rentoft M, Muller D, Tsilidis K, Heath AK, Keun H, Adamski J, Keski-Rahkonen P, Scalbert A, Gunter MJ, and Viallon V
- Subjects
- Male, Humans, Prospective Studies, Sphingomyelins, Lysophosphatidylcholines, Glutamine, Histidine, Risk Factors, Case-Control Studies, Phosphatidylcholines, Proline, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular epidemiology, Liver Neoplasms
- Abstract
Background: Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations., Methods: We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty., Results: Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types: glutamine, butyrylcarnitine, lysophosphatidylcholine a C18:2, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types: proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk., Conclusions: These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
38. Diet and BMI Correlate with Metabolite Patterns Associated with Aggressive Prostate Cancer.
- Author
-
Grenville ZS, Noor U, His M, Viallon V, Rinaldi S, Aglago EK, Amiano P, Brunkwall L, Chirlaque MD, Drake I, Eichelmann F, Freisling H, Grioni S, Heath AK, Kaaks R, Katzke V, Mayén-Chacon AL, Milani L, Moreno-Iribas C, Pala V, Olsen A, Sánchez MJ, Schulze MB, Tjønneland A, Tsilidis KK, Weiderpass E, Winkvist A, Zamora-Ros R, Key TJ, Smith-Byrne K, Travis RC, and Schmidt JA
- Subjects
- Animals, Body Mass Index, Cross-Sectional Studies, Fishes, Glutamates, Humans, Male, Prospective Studies, Risk Factors, Diet adverse effects, Prostatic Neoplasms etiology
- Abstract
Three metabolite patterns have previously shown prospective inverse associations with the risk of aggressive prostate cancer within the European Prospective Investigation into Cancer and Nutrition (EPIC). Here, we investigated dietary and lifestyle correlates of these three prostate cancer-related metabolite patterns, which included: 64 phosphatidylcholines and three hydroxysphingomyelins (Pattern 1), acylcarnitines C18:1 and C18:2, glutamate, ornithine, and taurine (Pattern 2), and 8 lysophosphatidylcholines (Pattern 3). In a two-stage cross-sectional discovery (n = 2524) and validation (n = 518) design containing 3042 men free of cancer in EPIC, we estimated the associations of 24 dietary and lifestyle variables with each pattern and the contributing individual metabolites. Associations statistically significant after both correction for multiple testing (False Discovery Rate = 0.05) in the discovery set and at p < 0.05 in the validation set were considered robust. Intakes of alcohol, total fish products, and its subsets total fish and lean fish were positively associated with Pattern 1. Body mass index (BMI) was positively associated with Pattern 2, which appeared to be driven by a strong positive BMI-glutamate association. Finally, both BMI and fatty fish were inversely associated with Pattern 3. In conclusion, these results indicate associations of fish and its subtypes, alcohol, and BMI with metabolite patterns that are inversely associated with risk of aggressive prostate cancer.
- Published
- 2022
- Full Text
- View/download PDF
39. Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study.
- Author
-
Fontvieille E, His M, Biessy C, Navionis AS, Torres-Mejía G, Ángeles-Llerenas A, Alvarado-Cabrero I, Sánchez GI, Navarro E, Cortes YR, Porras C, Rodriguez AC, Garmendia ML, Soto JL, Moyano L, Porter PL, Lin MG, Guenthoer J, Romieu I, and Rinaldi S
- Subjects
- Biomarkers, Case-Control Studies, Female, Humans, Inflammation complications, Interleukin-6, Interleukin-8, Latin America epidemiology, Leptin, Risk Factors, Tumor Necrosis Factor-alpha, Breast Neoplasms pathology
- Abstract
Background: Breast cancer incidence is increasing rapidly in Latin America, with a higher proportion of cases among young women than in developed countries. Studies have linked inflammation to breast cancer development, but data is limited in premenopausal women, especially in Latin America., Methods: We investigated the associations between serum biomarkers of chronic inflammation (interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), leptin, adiponectin) and risk of premenopausal breast cancer among 453 cases and 453 matched, population-based controls from Chile, Colombia, Costa Rica, and Mexico. Odds ratios (OR) were estimated using conditional logistic regression models. Analyses were stratified by size and hormonal receptor status of the tumors., Results: IL-6 (OR
per standard deviation (SD) = 1.33 (1.11-1.60)) and TNF-α (ORper SD = 1.32 (1.11-1.58)) were positively associated with breast cancer risk in fully adjusted models. Evidence of heterogeneity by estrogen receptor (ER) status was observed for IL-8 (P-homogeneity = 0.05), with a positive association in ER-negative tumors only. IL-8 (P-homogeneity = 0.06) and TNF-α (P-homogeneity = 0.003) were positively associated with risk in the largest tumors, while for leptin (P-homogeneity = 0.003) a positive association was observed for the smallest tumors only., Conclusions: The results of this study support the implication of chronic inflammation in breast cancer risk in young women in Latin America. Largest studies of prospective design are needed to confirm these findings in premenopausal women., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
40. Consumption of industrial processed foods and risk of premenopausal breast cancer among Latin American women: the PRECAMA study.
- Author
-
Romieu I, Khandpur N, Katsikari A, Biessy C, Torres-Mejía G, Ángeles-Llerenas A, Alvarado-Cabrero I, Sánchez GI, Maldonado ME, Porras C, Rodriguez AC, Garmendia ML, Chajés V, Aglago EK, Porter PL, Lin M, His M, Gunter MJ, Huybrechts I, and Rinaldi S
- Abstract
Ultra-processed food intake has been linked to an increased risk of breast cancer in Western populations. No data are available in the Latin American population although the consumption of ultra-processed foods is increasing rapidly in this region. We evaluated the association of ultra-processed food intake to breast cancer risk in a case-control study including 525 cases (women aged 20-45 years) and 525 matched population-based controls from Chile, Colombia, Costa Rica and Mexico. The degree of processing of foods was classified according to the NOVA classification. Overall, the major contributors to ultra-processed food intake were ready-to-eat/heat foods (18.2%), cakes and desserts (16.7%), carbonated and industrial fruit juice beverages (16.7%), breakfast cereals (12.9%), sausages and reconstituted meat products (12.1%), industrial bread (6.1%), dairy products and derivatives (7.6%) and package savoury snacks (6.1%). Ultra-processed food intake was positively associated with the risk of breast cancer in adjusted models (OR
T3-T1 =1.93; 95% CI=1.11 to 3.35). Specifically, a higher risk was observed with oestrogen receptor positive breast cancer (ORT3-T1 =2.44, (95% CI=1.01 to 5.90, P-trend=0.049), while no significant association was observed with oestrogen receptor negative breast cancer (ORT3-T1 =1.87, 95% CI=0.43 to 8.13, P-trend=0.36). Our findings suggest that the consumption of ultra-processed foods might increase the risk of breast cancer in young women in Latin America. Further studies should confirm these findings and disentangle specific mechanisms relating ultra-processed food intake and carcinogenic processes in the breast., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2022
- Full Text
- View/download PDF
41. Lifestyle correlates of eight breast cancer-related metabolites: a cross-sectional study within the EPIC cohort.
- Author
-
His M, Viallon V, Dossus L, Schmidt JA, Travis RC, Gunter MJ, Overvad K, Kyrø C, Tjønneland A, Lécuyer L, Rothwell JA, Severi G, Johnson T, Katzke V, Schulze MB, Masala G, Sieri S, Panico S, Tumino R, Macciotta A, Boer JMA, Monninkhof EM, Olsen KS, Nøst TH, Sandanger TM, Agudo A, Sánchez MJ, Amiano P, Colorado-Yohar SM, Ardanaz E, Vidman L, Winkvist A, Heath AK, Weiderpass E, Huybrechts I, and Rinaldi S
- Subjects
- Cohort Studies, Cross-Sectional Studies, Female, Humans, Life Style, Prospective Studies, Risk Factors, Breast Neoplasms epidemiology
- Abstract
Background: Metabolomics is a promising molecular tool for identifying novel etiological pathways leading to cancer. In an earlier prospective study among pre- and postmenopausal women not using exogenous hormones, we observed a higher risk of breast cancer associated with higher blood concentrations of one metabolite (acetylcarnitine) and a lower risk associated with higher blood concentrations of seven others (arginine, asparagine, phosphatidylcholines (PCs) aa C36:3, ae C34:2, ae C36:2, ae C36:3, and ae C38:2)., Methods: To identify determinants of these breast cancer-related metabolites, we conducted a cross-sectional analysis to identify their lifestyle and anthropometric correlates in 2358 women, who were previously included as controls in case-control studies nested within the European Prospective Investigation into Cancer and Nutrition cohort and not using exogenous hormones at blood collection. Associations of each metabolite concentration with 42 variables were assessed using linear regression models in a discovery set of 1572 participants. Significant associations were evaluated in a validation set (n = 786)., Results: For the metabolites previously associated with a lower risk of breast cancer, concentrations of PCs ae C34:2, C36:2, C36:3, and C38:2 were negatively associated with adiposity and positively associated with total and saturated fat intakes. PC ae C36:2 was also negatively associated with alcohol consumption and positively associated with two scores reflecting adherence to a healthy lifestyle. Asparagine concentration was negatively associated with adiposity. Arginine and PC aa C36:3 concentrations were not associated to any of the factors examined. For the metabolite previously associated with a higher risk of breast cancer, acetylcarnitine, a positive association with age was observed., Conclusions: These associations may indicate possible mechanisms underlying associations between lifestyle and anthropometric factors, and risk of breast cancer. Further research is needed to identify potential non-lifestyle correlates of the metabolites investigated., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
42. A New Pipeline for the Normalization and Pooling of Metabolomics Data.
- Author
-
Viallon V, His M, Rinaldi S, Breeur M, Gicquiau A, Hemon B, Overvad K, Tjønneland A, Rostgaard-Hansen AL, Rothwell JA, Lecuyer L, Severi G, Kaaks R, Johnson T, Schulze MB, Palli D, Agnoli C, Panico S, Tumino R, Ricceri F, Verschuren WMM, Engelfriet P, Onland-Moret C, Vermeulen R, Nøst TH, Urbarova I, Zamora-Ros R, Rodriguez-Barranco M, Amiano P, Huerta JM, Ardanaz E, Melander O, Ottoson F, Vidman L, Rentoft M, Schmidt JA, Travis RC, Weiderpass E, Johansson M, Dossus L, Jenab M, Gunter MJ, Lorenzo Bermejo J, Scherer D, Salek RM, Keski-Rahkonen P, and Ferrari P
- Abstract
Pooling metabolomics data across studies is often desirable to increase the statistical power of the analysis. However, this can raise methodological challenges as several preanalytical and analytical factors could introduce differences in measured concentrations and variability between datasets. Specifically, different studies may use variable sample types (e.g., serum versus plasma) collected, treated, and stored according to different protocols, and assayed in different laboratories using different instruments. To address these issues, a new pipeline was developed to normalize and pool metabolomics data through a set of sequential steps: (i) exclusions of the least informative observations and metabolites and removal of outliers; imputation of missing data; (ii) identification of the main sources of variability through principal component partial R-square (PC-PR2) analysis; (iii) application of linear mixed models to remove unwanted variability, including samples' originating study and batch, and preserve biological variations while accounting for potential differences in the residual variances across studies. This pipeline was applied to targeted metabolomics data acquired using Biocrates AbsoluteIDQ kits in eight case-control studies nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Comprehensive examination of metabolomics measurements indicated that the pipeline improved the comparability of data across the studies. Our pipeline can be adapted to normalize other molecular data, including biomarkers as well as proteomics data, and could be used for pooling molecular datasets, for example in international consortia, to limit biases introduced by inter-study variability. This versatility of the pipeline makes our work of potential interest to molecular epidemiologists.
- Published
- 2021
- Full Text
- View/download PDF
43. Biomarkers of mammographic density in premenopausal women.
- Author
-
His M, Lajous M, Gómez-Flores-Ramos L, Monge A, Dossus L, Viallon V, Gicquiau A, Biessy C, Gunter MJ, and Rinaldi S
- Subjects
- Adult, Body Mass Index, Breast diagnostic imaging, Breast Neoplasms blood, Breast Neoplasms diagnostic imaging, Cholesterol blood, Cross-Sectional Studies, Female, Humans, Mammography, Metabolomics, Mexico, Middle Aged, Phosphatidylcholines blood, Risk Factors, Sphingomyelins blood, Biomarkers blood, Breast Density physiology, Premenopause
- Abstract
Background: While mammographic density is one of the strongest risk factors for breast cancer, little is known about its determinants, especially in young women. We applied targeted metabolomics to identify circulating metabolites specifically associated with mammographic density in premenopausal women. Then, we aimed to identify potential correlates of these biomarkers to guide future research on potential modifiable determinants of mammographic density., Methods: A total of 132 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, sphingolipids, hexose) were measured by tandem liquid chromatography/mass spectrometry in plasma samples from 573 premenopausal participants in the Mexican Teachers' Cohort. Associations between metabolites and percent mammographic density were assessed using linear regression models, adjusting for breast cancer risk factors and accounting for multiple tests. Mean concentrations of metabolites associated with percent mammographic density were estimated across levels of several lifestyle and metabolic factors., Results: Sphingomyelin (SM) C16:1 and phosphatidylcholine (PC) ae C30:2 were inversely associated with percent mammographic density after correction for multiple tests. Linear trends with percent mammographic density were observed for SM C16:1 only in women with body mass index (BMI) below the median (27.4) and for PC ae C30:2 in women with a BMI over the median. SM C16:1 and PC ae C30:2 concentrations were positively associated with cholesterol (total and HDL) and inversely associated with number of metabolic syndrome components., Conclusions: We identified new biomarkers associated with mammographic density in young women. The association of these biomarkers with mammographic density and metabolic parameters may provide new perspectives to support future preventive actions for breast cancer., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
44. Body size, silhouette trajectory and the risk of breast cancer in a Moroccan case-control study.
- Author
-
Khalis M, Dossus L, Rinaldi S, Biessy C, Moskal A, Charaka H, Fort E, His M, Mellas N, Nejjari C, Charbotel B, Soliman AS, Romieu I, Chajès V, Gunter MJ, Huybrechts I, and El Rhazi K
- Subjects
- Adult, Age Factors, Breast Neoplasms physiopathology, Case-Control Studies, Female, Humans, Middle Aged, Morocco epidemiology, Postmenopause physiology, Premenopause physiology, Reproductive History, Risk Assessment methods, Risk Factors, Adiposity physiology, Body Mass Index, Breast Neoplasms epidemiology, Waist Circumference physiology
- Abstract
Background: There is convincing evidence demonstrating that body size characteristics such as adiposity and height are associated with breast cancer in westernized countries. However, little is known about this relationship in North African countries currently undergoing nutritional transition and industrialization. The aim of this study was to explore associations between various body size characteristics, silhouette trajectories and the risk of breast cancer among Moroccan women., Methods: In this case-control study conducted in the Fez region (2016-2017), detailed measures of body size were collected for 300 cases of breast cancer and 300 matched controls. Unconditional logistic regression was used to assess the association between body size and breast cancer risk adjusting for confounding factors., Results: Higher waist circumference and hip circumference were positively associated with breast cancer risk in pre- (highest [T3] vs. lowest tertile [T1]: OR = 2.92, 95% confidence intervals [CI]: 1.33-6.42; OR = 3.00, 95% CI: 1.42-6.33, respectively) and post-menopausal women (T3 vs. T1: OR = 4.46, 95% CI: 1.86-10.66; OR = 4.08, 95% CI: 1.76-9.42, respectively). Body shape at younger ages (6-11 years) was inversely associated with the risk of breast cancer in premenopausal women (large vs. lean silhouette: OR = 0.31, 95% CI: 0.12-0.80). Women with the greatest increase in body shape trajectory had higher risk for both pre- and post-menopausal breast cancer (T3 vs. T1: OR = 2.74, 95% CI: 1.03-7.26; OR = 3.56, 95% CI: 1.34-9.44, respectively)., Conclusion: Our findings suggest that adiposity, body shape at younger ages, and silhouette trajectory may play a role in the development of pre- and post-menopausal breast cancer among Moroccan women. Larger-scale prospective studies are needed to confirm our findings and to explore these associations with breast cancer subtypes.
- Published
- 2020
- Full Text
- View/download PDF
45. Anthropometry, body shape in early-life and risk of premenopausal breast cancer among Latin American women: results from the PRECAMA study.
- Author
-
His M, Biessy C, Torres-Mejía G, Ángeles-Llerenas A, Alvarado-Cabrero I, Sánchez GI, Borrero M, Porras C, Rodriguez AC, Garmendia ML, Olivier M, Porter PL, Lin M, Gunter MJ, Romieu I, and Rinaldi S
- Subjects
- Adult, Body Mass Index, Breast Neoplasms physiopathology, Case-Control Studies, Female, Humans, Incidence, Latin America epidemiology, Middle Aged, Obesity, Abdominal physiopathology, Risk Factors, Young Adult, Adiposity physiology, Breast Neoplasms epidemiology, Obesity, Abdominal epidemiology, Premenopause, Waist Circumference physiology
- Abstract
Cumulating evidence in Caucasian women suggests a positive association between height and premenopausal breast cancer risk and a negative association with overall adiposity; however data from Latin America are scarce. We investigated the associations between excess adiposity, body shape evolution across life, and risk of premenopausal breast cancer among 406 cases (women aged 20-45) and 406 matched population-based controls from Chile, Colombia, Costa Rica, and Mexico. Negative associations between adult adiposity and breast cancer risk were observed in adjusted models (body mass index (BMI): Odds ratio (OR) per 1 kg/m
2 = 0.93; 95% confidence interval = 0.89-0.96; waist circumference (WC): OR per 10 cm = 0.81 (0.69-0.96); hip circumference (HC): OR per 10 cm = 0.80 (0.67-0.95)). Height and leg length were not associated with risk. In normal weight women (18.5 ≤ BMI < 25), women with central obesity (WC > 88 cm) had an increased risk compared to women with normal WC (OR = 3.60(1.47-8.79)). Residuals of WC over BMI showed positive associations when adjusted for BMI (OR per 10 cm = 1.38 (0.98-1.94)). Body shape at younger ages and body shape evolution were not associated with risk. No heterogeneity was observed by receptor status. In this population of Latin American premenopausal women, different fat distributions in adulthood were differentially associated with risk of breast cancer.- Published
- 2020
- Full Text
- View/download PDF
46. Nutrient-wide association study of 92 foods and nutrients and breast cancer risk.
- Author
-
Heath AK, Muller DC, van den Brandt PA, Papadimitriou N, Critselis E, Gunter M, Vineis P, Weiderpass E, Fagherazzi G, Boeing H, Ferrari P, Olsen A, Tjønneland A, Arveux P, Boutron-Ruault MC, Mancini FR, Kühn T, Turzanski-Fortner R, Schulze MB, Karakatsani A, Thriskos P, Trichopoulou A, Masala G, Contiero P, Ricceri F, Panico S, Bueno-de-Mesquita B, Bakker MF, van Gils CH, Olsen KS, Skeie G, Lasheras C, Agudo A, Rodríguez-Barranco M, Sánchez MJ, Amiano P, Chirlaque MD, Barricarte A, Drake I, Ericson U, Johansson I, Winkvist A, Key T, Freisling H, His M, Huybrechts I, Christakoudi S, Ellingjord-Dale M, Riboli E, Tsilidis KK, and Tzoulaki I
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms diagnosis, Cohort Studies, Female, Humans, Middle Aged, Nutrition Assessment, Prospective Studies, Risk Factors, Young Adult, Breast Neoplasms diet therapy, Breast Neoplasms epidemiology, Diet, Dietary Fiber standards, Feeding Behavior psychology, Nutrients, Surveys and Questionnaires statistics & numerical data
- Abstract
Background: Several dietary factors have been reported to be associated with risk of breast cancer, but to date, unequivocal evidence only exists for alcohol consumption. We sought to systematically assess the association between intake of 92 foods and nutrients and breast cancer risk using a nutrient-wide association study., Methods: Using data from 272,098 women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, we assessed dietary intake of 92 foods and nutrients estimated by dietary questionnaires. Cox regression was used to quantify the association between each food/nutrient and risk of breast cancer. A false discovery rate (FDR) of 0.05 was used to select the set of foods and nutrients to be replicated in the independent Netherlands Cohort Study (NLCS)., Results: Six foods and nutrients were identified as associated with risk of breast cancer in the EPIC study (10,979 cases). Higher intake of alcohol overall was associated with a higher risk of breast cancer (hazard ratio (HR) for a 1 SD increment in intake = 1.05, 95% CI 1.03-1.07), as was beer/cider intake and wine intake (HRs per 1 SD increment = 1.05, 95% CI 1.03-1.06 and 1.04, 95% CI 1.02-1.06, respectively), whereas higher intakes of fibre, apple/pear, and carbohydrates were associated with a lower risk of breast cancer (HRs per 1 SD increment = 0.96, 95% CI 0.94-0.98; 0.96, 95% CI 0.94-0.99; and 0.96, 95% CI 0.95-0.98, respectively). When evaluated in the NLCS (2368 cases), estimates for each of these foods and nutrients were similar in magnitude and direction, with the exception of beer/cider intake, which was not associated with risk in the NLCS., Conclusions: Our findings confirm a positive association of alcohol consumption and suggest an inverse association of dietary fibre and possibly fruit intake with breast cancer risk.
- Published
- 2020
- Full Text
- View/download PDF
47. Prospective analysis of circulating metabolites and breast cancer in EPIC.
- Author
-
His M, Viallon V, Dossus L, Gicquiau A, Achaintre D, Scalbert A, Ferrari P, Romieu I, Onland-Moret NC, Weiderpass E, Dahm CC, Overvad K, Olsen A, Tjønneland A, Fournier A, Rothwell JA, Severi G, Kühn T, Fortner RT, Boeing H, Trichopoulou A, Karakatsani A, Martimianaki G, Masala G, Sieri S, Tumino R, Vineis P, Panico S, van Gils CH, Nøst TH, Sandanger TM, Skeie G, Quirós JR, Agudo A, Sánchez MJ, Amiano P, Huerta JM, Ardanaz E, Schmidt JA, Travis RC, Riboli E, Tsilidis KK, Christakoudi S, Gunter MJ, and Rinaldi S
- Subjects
- Adult, Aged, Biomarkers analysis, Biomarkers metabolism, Breast Neoplasms diagnosis, Breast Neoplasms epidemiology, Case-Control Studies, Cohort Studies, Female, Humans, Incidence, Mass Spectrometry, Middle Aged, Prospective Studies, Risk Factors, Biomarkers blood, Breast Neoplasms blood, Metabolomics methods
- Abstract
Background: Metabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk., Methods: A nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression., Results: Among women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70-0.90), asparagine (OR = 0.83 (0.74-0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76-0.90)), aa C36:3 (OR = 0.84 (0.77-0.93)), ae C34:2 (OR = 0.85 (0.78-0.94)), ae C36:2 (OR = 0.85 (0.78-0.88)), and ae C38:2 (OR = 0.84 (0.76-0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11-1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06-1.24)) and PC ae C36:3 (OR = 0.88 (0.82-0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity., Conclusions: These findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies.
- Published
- 2019
- Full Text
- View/download PDF
48. Stand out as a speaker.
- Author
-
His M
- Published
- 2019
- Full Text
- View/download PDF
49. [Obesity and Cancer].
- Author
-
Lauby-Secretan B, Dossus L, Marant-Micallef C, and His M
- Subjects
- Adult, Child, Cocarcinogenesis, Comorbidity, Diet adverse effects, Energy Metabolism, Exercise, Female, Global Health, Gonadal Steroid Hormones physiology, Guidelines as Topic, Humans, Inflammation, Insulin physiology, Insulin-Like Growth Factor I physiology, Male, Neoplasms etiology, Neoplasms prevention & control, Organ Specificity, Overweight complications, Overweight physiopathology, Prevalence, Risk Factors, World Health Organization, Neoplasms epidemiology, Overweight epidemiology
- Abstract
In the past decades, obesity and overweight prevalence has been rising worldwide, in both men and women. In France, the prevalence of overweight in adults was 49% in 2015 (54% among men and 44% among women), including 17% of obese adults. According to the last evaluation performed by IARC in 2017, overweight and obesity are established risk factors for 13 cancer sites with risk estimates per 5kg/m
2 varying largely depending on the cancer site. In 2015 in France, 5.4% of cancer cases could be attributed to excess weight, corresponding to 18,600 cases, including 3400 colon cancers, 2600 kidney cancers, 4500 breast cancers and 2500 endometrial cancers. Obesity is also related to worse prognosis for some cancers, in particular breast and colon cancers. Obesity in children and adolescents, also rising in many countries, has also been associated to an increase in adult cancer risk. A major cause of obesity is a disequilibrium in energy balance favoured by a diet rich in processed food, red meat, trans and saturated fatty acids, sweetened foods and beverages and poor in fruits and vegetables, legumes and whole grains. Main national and international recommendations to reduce the prevalence of obesity are to have a balanced diet and regular physical activity., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
50. An exploration of gender-based violence in eastern Myanmar in the context of political transition: findings from a qualitative sexual and reproductive health assessment.
- Author
-
Tanabe M, Greer A, Leigh J, Modi P, Davis WW, Mhote PP, Htoo EM, Otterness CM Jr, and Parmar P
- Subjects
- Adolescent, Adult, Community Health Services, Female, Focus Groups, Gender-Based Violence statistics & numerical data, Health Services Accessibility, Humans, Male, Middle Aged, Myanmar, Politics, Qualitative Research, Reproductive Health, Reproductive Health Services, Sexual Health, Young Adult, Gender-Based Violence psychology, Sexual Partners psychology, Social Norms
- Abstract
In March 2011, the Myanmar Government transitioned to a nominally civilian parliamentary government, resulting in dramatic increases in international investments and tenuous peace in some regions. In March 2015, Community Partners International, the Women's Refugee Commission, and four community-based organisations (CBOs) assessed community-based sexual and reproductive health (SRH) services in eastern Myanmar amidst the changing political contexts in Myanmar and Thailand. The team conducted 12 focus group discussions among women of reproductive age (18-49 years) with children under five and interviewed 12 health workers in Kayin State, Myanmar. In Mae Sot and Chiang Mai, Thailand, the team interviewed 20 representatives of CBOs serving the border regions. Findings are presented through the socioecological lens to explore gender-based violence (GBV) specifically, to examine continued and emerging issues in the context of the political transition. Cited GBV includes ongoing sexual violence/rape by the military and in the community, trafficking, intimate partner violence, and early marriage. Despite the political transition, women continue to be at risk for military sexual violence, are caught in the burgeoning economic push-pull drivers, and experience ongoing restrictive gender norms, with limited access to SRH services. There is much fluidity, along with many connections and interactions among the contributing variables at all levels of the socioecological model; based on a multisectoral response, continued support for innovative, community-based SRH services that include medical and psychosocial care are imperative for ethnic minority women to gain more agency to freely exercise their SR rights.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.